Hoth Therapeutics' shares surged more than 250% to $3 following positive interim results from its Phase 2a trial of HT-001, aimed at treating skin toxicities from EGFR inhibitors in cancer patients.
As the Nasdaq and S&P 500 looked to add to Friday's gains, Dow Jones Industrial Average member American Express — along with Boston Scientific, GE Vernova and Block — traded in or near buy zones ...
Results that may be inaccessible to you are currently showing.